While researchers are grateful they can offer patients one of the two approved stabilizers, better therapeutics are still ...
The approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most ...
The tiny protein known as transthyretin can cause big problems in the body when it misfolds after secretion. While healthy transthyretin moves hormones through blood and spinal fluid, misfolded ...
Palo Alto, California Thursday, February 13, 2025, 12:00 Hrs [IST] ...
“The methodologies we’ve developed have opened new doors to avenues of treatment that could one day protect patients from not just TTR amyloidosis, but other amyloid diseases as well,” says ...
Nearly 3 months after the FDA green-lit the TTR stabilizer, it joins tafamidis as the second therapy in Europe for the ...
Hereditary transthyretin-mediated amyloidosis (hATTR) is a rare, long-term, progressive disease that causes a buildup of a protein called transthyretin (TTR). TTR protein is made in the liver ...
It is being developed for both inherited and non-inherited forms of TTR amyloidosis, a systemic, progressive and fatal condition. There are estimated to be up to half a million people worldwide ...
The EU is the second market for the drug after the US, where it was approved under the Attruby brand name last November, on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback